1. Frank Collins Frank Collins United States says:

    It appears the human digestive system metabolizes niclosamide primarily
    though the enzymes  CYP1A2 and UGT1A1.  As was discovered years
    ago, through the use of grapefruit juice to mask the taste of a particular
    medication, its enzyme inhibitors can also have a troublesome impact on the absorption and
    serum levels of many drugs.  Might niclosamide’s poor solubility be
    just one part of the problem, with enzyme metabolism more critical?

    Consider the possibility of inhibiting enzymes CYP1A2 and UGT1A1
    through the early p.o.administration of select drugs and supplements,
    prior to ingestion of niclosamide.  For example, cimetidine  and melatonin
    are proven, relatively benign inhibitors of CYP1A2.  (Ciprofloxacin inhibits
    CYP1A2 as well but with more possible side effects). Acetacin, isolated
    from turnera diffusa  (Damiana) and KaeminhibitUGT1A1.  

    Another route - rectal suppository- though never mentioned in the literature, could also evade  its first-pass enzyme degradation. Many water-insoluble meds are administered via suppository.  Why not try niclosamide?

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment